
1. Clin Microbiol Infect. 2015 Oct;21(10):910-6. doi: 10.1016/j.cmi.2015.05.039.
Epub 2015 Jun 5.

Group B streptococcus neonatal invasive infections, France 2007-2012.

Joubrel C(1), Tazi A(1), Six A(2), Dmytruk N(3), Touak G(3), Bidet P(4), Raymond 
J(5), Trieu Cuot P(6), Fouet A(7), Kernéis S(8), Poyart C(9).

Author information: 
(1)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpitaux
Universitaires Paris Centre Site Cochin, France; Centre National de Référence des
Streptocoques, France; DHU Risques et Grossesse, Assistance Publique-Hôpitaux de 
Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; INSERM U 
1016, Institut Cochin, Team 'Barriers and Pathogens', France; CNRS UMR 8104,
France.
(2)Université Paris Descartes, Sorbonne Paris Cité, France; INSERM U 1016,
Institut Cochin, Team 'Barriers and Pathogens', France; CNRS UMR 8104, France.
(3)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpitaux
Universitaires Paris Centre Site Cochin, France; Centre National de Référence des
Streptocoques, France; DHU Risques et Grossesse, Assistance Publique-Hôpitaux de 
Paris, France.
(4)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpital
Robert Debré, France.
(5)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpitaux
Universitaires Paris Centre Site Cochin, France; DHU Risques et Grossesse,
Assistance Publique-Hôpitaux de Paris, France; Université Paris Descartes,
Sorbonne Paris Cité, France.
(6)Institut Pasteur, Unité de Biologie des Bactéries Pathogènes à Gram Positif,
France; CNRS ERL3526, Paris, France.
(7)Centre National de Référence des Streptocoques, France; DHU Risques et
Grossesse, Assistance Publique-Hôpitaux de Paris, France; Université Paris
Descartes, Sorbonne Paris Cité, France; INSERM U 1016, Institut Cochin, Team
'Barriers and Pathogens', France; CNRS UMR 8104, France.
(8)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpitaux
Universitaires Paris Centre Site Cochin, France; Centre National de Référence des
Streptocoques, France; DHU Risques et Grossesse, Assistance Publique-Hôpitaux de 
Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France.
(9)Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, Hôpitaux
Universitaires Paris Centre Site Cochin, France; Centre National de Référence des
Streptocoques, France; DHU Risques et Grossesse, Assistance Publique-Hôpitaux de 
Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France; INSERM U 
1016, Institut Cochin, Team 'Barriers and Pathogens', France; CNRS UMR 8104,
France; CNRS ERL3526, Paris, France. Electronic address:
claire.poyart@cch.aphp.fr.

Streptococcus agalactiae (group B streptococcus (GBS)) is the leading cause of
invasive infections among newborns in industrialized countries, with two
described syndromes: early-onset disease (EOD) and late-onset disease (LOD).
Since the introduction in many countries of intrapartum antibioprophylaxis (IAP),
the incidence of EOD has dramatically decreased, whereas that of LOD remains
unchanged. We describe the clinical and bacteriological characteristics of 438
GBS neonatal invasive infections notified to the French National Reference Centre
for Streptococci in France from 2007 to 2012. Clinical data were retrieved from
hospitalization reports or questionnaires. Capsular type, assignment to the
hypervirulent clonal complex (CC)17 and antibiotic susceptibility profiles were
determined. One hundred and seventy-four (39.7%) and 264 (60.3%) isolates were
responsible for EOD, including death in utero, and LOD, respectively. EOD was
associated with bacteraemia (n = 103, 61%) and LOD with meningitis (n = 145,
55%). EOD was mainly due to capsular polysaccharide (CPS) III isolates (n = 99,
57%) and CPS Ia isolates (n = 40, 23%), and CPS III isolates were responsible for
80% (n = 211) of LOD cases. CC17 accounted for 80% (n = 121) of CPS III isolates 
responsible for meningitis (n = 151; total cases of meningitis, 188). Bad outcome
risk factors were low gestational age and low birthweight. LOD represents almost 
60% of cases of neonatal GBS disease in France and other countries in which IAP
has been implemented. This observation reinforces the need to develop new
prevention strategies targeting CC17, which is predominant in GBS neonatal
infections.

Copyright © 2015 European Society of Clinical Microbiology and Infectious
Diseases. Published by Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.cmi.2015.05.039 
PMID: 26055414  [Indexed for MEDLINE]

